Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Qian Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Yufu Li(Henan Cancer Hospital), Yue-Rong Shuang(Jiangxi Provincial Cancer Hospital), Hong Cen(Tumor Hospital of Guangxi Medical University), Zhigang Peng(Guangxi Medical University), Ye Guo(Army Medical University), Jianqiu Wu(Jiangsu Cancer Hospital), Zheng Ge(Southeast University), Lei Fan(Jiangsu Province Hospital), Chuan Jin(Guangzhou Medical University), Haiyan Yang(Zhejiang Cancer Hospital), Xin Du(Shenzhen Second People's Hospital), Hui Zhou(Hunan Cancer Hospital), Jie Cui(Guangzhou University), Hang Su(307th Hospital of Chinese People’s Liberation Army), Liping Xie(First Affiliated Hospital of Xiamen University), Mingzhi Zhang(Chinese Academy of Sciences), Hongyu Zhang(Northwest Institute of Eco-Environment and Resources), Li Liu(Air Force Medical University), Zhen Wang(Huanghuai University), Liling Zhang(Union Hospital), Ru Feng(Chinese Academy of Medical Sciences & Peking Union Medical College), Ming Jiang(Nanjing Medical University), Zhao Wang(Hainan University), Xiaoyan Ke(Peking University), Weihua Zhang(Zhejiang A & F University), Xin Du(Changchun University of Science and Technology), Yaming Xi(First Hospital of Lanzhou University), Shengyu Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Liping Ma(Sichuan University), Yuhuan Gao(Hebei Medical University), Yang Zhang(Anhui Medical University), Huilai Zhang(Shanxi Medical University), Lin Wang(The Synergetic Innovation Center for Advanced Materials), Fan Xie
Journal of Hematology & Oncology
January 12, 2021
Cited by 64


Related Papers